EMAIL THIS PAGE TO A FRIEND

BMC research notes

Effects of oxygen on the antigenic landscape of prostate cancer cells.


PMID 26581192

Abstract

Use of allogeneic cancer cells-based immunotherapy for treatment of established prostate cancer (PCa) has only been marginally effective. One reason for failure could stem from the mismatch of antigenic signatures of vaccine cells and cancer in situ. Hence, it is possible that vaccine cells expressed antigens differently than tumor cells in situ. We hypothesized that cells grown in vitro at low oxygen tension (pO2) provide a better antigen match to tumors in situ and could reveal a more relevant antigenic landscape than cells grown in atmospheric pO2. We tested this hypothesis by comparing PCa cells propagated at pO2 = 2 kPa and 20 kPa. To identify potential tumor-associated antigens (TAAs), we prepared PCa cell lysates, resolved them by two-dimensional electrophoresis and immunoblotting using spontaneous antibodies from plasma derived from PCa patients and control subjects. Antibody-labeled spots were analyzed by MALDI-TOF mass spectrometry and validated by ELISA. We selected hypoxia-regulated HSP70 and hnRNP L and hypoxia-independent HSP60 and determined the frequency of plasma samples reacting with these molecules. Frequency of HSP60-reactive plasma was low in healthy controls [1.3 % (1/76)], while it was elevated in PCa patients [13.0 % (7/54); p < 0.05]. These data suggest a humoral immune response to HSP60 in PCa. Levels of autoantibodies to HSP70 did not differ from healthy controls [3.7 % (2/54)] in PCa patients [5.3 % (2/38)]. Similarly, hnRNP L autoantibodies did no differ between healthy controls [6.1 % (3/49)] and PCa patients [5.3 % (2/38)]. Overall our results suggest the value of hypoxia as a modifier of the cellular and antigenic landscape of PCa cells. By modifying the immune reactivity of PCa cells in culture, manipulation of pO2 can be proposed as a new avenue for improving diagnosis, prognosis and immunotherapy for PCa.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

226947
3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate, 98%
C32H58N2O7S · xH2O
271004
Acetonitrile, anhydrous, 99.8%
C2H3N
675415
Acetonitrile, HPLC Plus, ≥99.9%, poly-coated bottles
C2H3N
437557
Acetonitrile, ≥99.5%, ACS reagent
C2H3N
270717
Acetonitrile, HPLC grade, ≥99.93%
C2H3N
L010000-HH
Acetonitrile, for DNA synthesis
C2H3N
01-0650
Acetonitrile, ≥99.8%, for HPLC
C2H3N
01-0623
Acetonitrile, for residue analysis, JIS 5000
C2H3N
01-0645
Acetonitrile, for chromatography
C2H3N
733466
Acetonitrile, electronic grade, 99.999% trace metals basis
C2H3N
L011800
Acetonitrile
C2H3N
576956
Acetonitrile solution, contains 0.1 % (v/v) formic acid, for HPLC
C2H3N
574732
Acetonitrile solution, contains 0.1 % (v/v) trifluoroacetic acid, for HPLC
C2H3N
574724
Acetonitrile solution, contains 0.05 % (v/v) trifluoroacetic acid
C2H3N
679186
Acetonitrile solution, contains 5 % (v/v) water, 0.05 % (w/v) ammonium formate, 0.1 % (v/v) formic acid, for HPLC
C2H3N
685461
Acetonitrile solution, contains 10.0% acetone, 40.0% 2-propanol, 0.05% formic acid
C2H3N
703664
Acetonitrile solution, NMR reference standard, 0.23 wt. % in D2O (99.9 atom % D), water 0.05 wt. %, NMR tube size 6.5 mm × 8 in.
C2H3N
43816
DL-Dithiothreitol solution, BioUltra, for molecular biology, ~1 M in H2O
C4H10O2S2
646563
DL-Dithiothreitol solution, 1 M in H2O
C4H10O2S2
T7875
Thiourea, ReagentPlus®, ≥99.0%
CH4N2S
T8656
Thiourea, ACS reagent, ≥99.0%
CH4N2S
T6508
Trifluoroacetic acid, ReagentPlus®, 99%
C2HF3O2
30-4310
Trifluoroacetic acid, SAJ special grade, ≥99.0%
C2HF3O2
91709
Trifluoroacetic acid solution, BioReagent, suitable for protein sequencing, ~25% in H2O
C2HO2F3
U0631
Urea, BioXtra, pH 7.5-9.5 (20 °C, 5 M in H2O)
CH4N2O
U5378
Urea, powder, BioReagent, for molecular biology, suitable for cell culture
CH4N2O
U4883
Urea, 8 M (after reconstitution with 16 mL high purity water)
CH4N2O
U6504
Urea, for electrophoresis
CH4N2O
U4884
Urea, meets USP testing specifications
CH4N2O
U5128
Urea, ACS reagent, 99.0-100.5%
CH4N2O